HSBC's Top 10 Buy-Rated Stocks to Watch This Earnings Season
N.R. Finch
HSBC screened 10 buy-rated stocks ahead of Q2 earnings across tech, industrials, pharma, financials, and hospitality — effectively a concentrated bet on where the firm sees the clearest growth narratives for the second half.
Why do four tech giants all make the cut?
Alphabet, Microsoft, Amazon, and Meta all appear — the common thread is that their AI businesses have moved from spending phase to revenue phase.
This means → HSBC is not betting on "AI as a concept" but on companies where AI is already generating income.
The numbers: Azure AI revenue up 40% year-on-year; AWS custom-chip annualized recurring revenue at $20 billion; Meta ad revenue up 33% in Q1 driven by AI recommendation tools; Alphabet's 8th-gen TPU now available to external clients.
In plain terms = these four are not telling a story — they are showing a scorecard.
Who are the "pick-and-shovel" plays for data centers?
HSBC picked Caterpillar and Vertiv in industrials — both ride the data-center buildout wave.
Caterpillar's case: AI data centers need massive prime power; the company plans to expand capacity to 65 GW by 2030. Mining equipment also benefits from rising critical-mineral spending.
Vertiv draws roughly 80% of revenue from data centers — the highest data-center exposure among U.S. capital-goods stocks.
This means → HSBC believes power and cooling complexity will keep rising, making the equipment sellers more certain bets than the data-center builders themselves.
Why does a solar tracker company appear on this list?
Nextracker — a solar tracker maker — has a backlog exceeding $5.25 billion and is broadening its addressable market through strategic acquisitions.
A new Middle East joint venture extends its international footprint.
This reflects a specific HSBC view: energy infrastructure is not just legacy power — renewables hardware suppliers also ride the data-center expansion cycle.
What makes the pharma and financials picks different?
AbbVie is here for two immunology drugs, Skyrizi and Rinvoq — HSBC expects them to sustain best-in-class growth into the early 2030s. The Apogee acquisition adds a new growth vector in atopic dermatitis.
Wells Fargo is a valuation call: just 10.8× estimated 2027 earnings, with improving net interest income and elevated buybacks.
In plain terms = AbbVie is a bet on long product lifecycles; Wells Fargo is a bet on a cheap price — two entirely different kinds of "bargain."
What earns Marriott a spot on the buy list?
Marriott International's core asset is not the hotels themselves — it is a 283-million-member Bonvoy loyalty program, co-branded credit cards, and branded residences.
The asset-light model delivers high operating leverage; steady unit growth supports long-term cash flow.
This means → HSBC values Marriott's ability to turn hospitality into a financial product — the loyalty system and credit cards are the real profit engine.
What signal does this list send as a whole?
The 10 names span tech, industrials, energy, pharma, financials, and hospitality — each with different cycle characteristics.
This reflects a deliberate spread: HSBC is not making a single thematic bet but picking the clearest growth narrative in each sector.
Earnings season is the proving ground — whether these companies can back their stories with numbers will determine how well HSBC's list holds up.
Content is for reference only, not financial advice.